Dr. Matulonis Discusses QoL Data from GOG-258 in Endometrial Cancer

Ursula A. Matulonis, MD
Published: Thursday, Aug 16, 2018



Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the quality-of-life (QoL) outcomes from the GOG-258 trial in patients with endometrial cancer.

GOG-258 was a randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel versus carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma. This trial included patients with stage III and stage IVA disease.

Matulonis says that in both groups, patients experienced significant neuropathy, which was attributed to the chemotherapy given. Patients who received radiation had more gastrointestinal toxicities, which were present at the 1-year mark. Matulonis says that these are important factors to consider when selecting therapy.
SELECTED
LANGUAGE


Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the quality-of-life (QoL) outcomes from the GOG-258 trial in patients with endometrial cancer.

GOG-258 was a randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel versus carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma. This trial included patients with stage III and stage IVA disease.

Matulonis says that in both groups, patients experienced significant neuropathy, which was attributed to the chemotherapy given. Patients who received radiation had more gastrointestinal toxicities, which were present at the 1-year mark. Matulonis says that these are important factors to consider when selecting therapy.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Community Practice Connections™: Show Me the Data™: Leveraging Evidence to Optimize Applications of PARP Inhibitor Strategies in Ovarian CancerJun 29, 20191.5
Publication Bottom Border
Border Publication
x